Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the ...

Trial investigates macrophage re-reprogramming immunotherapy bexmarilimab in combination with azacitidine to prevent relapse in MRD-positive AML after stem cell transplantation. TURKU, FI / ACCESS ...

Early findings from the ongoing MIRACLE clinical trial suggest that the investigational drug annamycin, given with cytarabine, may help more patients with relapsed or refractory acute myeloid leukemia ...

Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein ...

Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of the subjects treated to date represent ...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...

Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates ...

CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. Researchers at Baylor College of Medicine, University of Veterinary ...

The study, titled “Epigenetic regulation of non-canonical menin targets modulates menin inhibitor response in acute myeloid leukemia,” was recently published in Blood and focuses on acute myeloid ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that suppress their growth ...